Studies have shown that PD-1/PD-L1 axis can be hijacked by tumors as a co-inhibitory pathway to compromise the immune response toward cancer via blocking proliferation, induction of apoptosis by CTL, and promotion of regulatory T cell differentiation, which eventually induces an immunosuppressive microenvironment in tumor (25, 26). This evidence concerns the gene PDCD1 and neoplasm.